Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
AstraZeneca
AstraZeneca
Incyte Corporation
Hoffmann-La Roche
Bristol-Myers Squibb
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Hoffmann-La Roche
Children's Oncology Group
AstraZeneca
Bristol-Myers Squibb
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
AstraZeneca
Bristol-Myers Squibb
Shanghai Henlius Biotech
Incyte Corporation
Hoffmann-La Roche
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AstraZeneca
Children's Oncology Group
Merck Sharp & Dohme LLC
AstraZeneca
Eli Lilly and Company
Bristol-Myers Squibb
AstraZeneca
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital